You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華檢醫療(01931.HK)擬攜手華大共贏共同建立華檢華大共贏創新藥知識產權代幣化基金
格隆匯 07-30 21:42

格隆匯7月30日丨華檢醫療(01931.HK)公吿,於2025年7月30日,公司與華大共贏(深圳)股權投資基金管理有限公司("華大共贏")訂立戰略合作框架協議,共同建立華檢華大共贏創新藥知識產權代幣化基金(IVD-BGICoWin)("基金"),該基金將於香港╱美國或其他海外地區投資於公司NewCo+RWAWeb3交易所生態運作模式下的項目。

根據框架協議,公司或其指定實體將作為有限合夥人向基金出資,而華大共贏或其指定實體將作為普通合夥人負責NewCo創新藥RWA基金的管理的運營及管理。應公司的要求,華大共贏將篩選符合公司戰略需求的優質創新制藥公司或目標資產,並提供推廣目標項目、專項盡職調查、融資協調以及交易方案設計等服務,涵蓋國內外的創新醫療及創新藥領域。

華大共贏為一間於中國證券投資基金業協會登記的私募股權基金管理公司,作為由生物技術領導者華大基因發起的企業風險投資(CVC)實體,擁有多年於創新醫療及創新藥領域的國內外投資經驗及項目資源。

董事會認為,戰略合作將推進本公司通過"NewCo+RWA+穩定幣"的三管齊下策略擴展業務佈局,並加強其於重塑全球醫療創新藥物資產價值鏈中的角色。因此,董事會認為,訂立框架協議符合公司及其股東整體利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account